Pointe Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pointe Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$472K	Sell	757 -60	-7%	-$40.8K	0.21%	92
2026 Q1	$631K	Sell	817 -29	-3%	-$22.2K	0.31%	69
2025 Q4	$653K	Buy	846 +127	+18%	+$86.2K	0.32%	65
2025 Q3	$404K	Buy	719 +194	+37%	+$110K	0.2%	110
2025 Q2	$276K	Buy	525 +6	+1%	+$3.35K	0.14%	129
2025 Q1	$329K	Sell	519 -9	-2%	-$6.19K	0.19%	114
2024 Q4	$376K	Buy	528 +187	+55%	+$157K	0.22%	110
2024 Q3	$358K	Buy	+341	New	+$379K	0.21%	112
2023 Q2	–	Sell	-132	Closed	-$108K	–	337
2023 Q1	$108K	Buy	+132	New	+$99.6K	0.08%	181
2022 Q2	–	Sell	-571	Closed	-$399K	–	153
2022 Q1	$399K	Buy	571 +14	+3%	+$8.86K	0.25%	100
2021 Q4	$352K	Buy	+557	New	+$342K	0.21%	113

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pointe Capital Management's REGN Position: Q2 2026 in Review

Pointe Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 7.3% in Q2 2026, selling an estimated $40.8K and leaving 757 shares worth $472K. The position accounts for 0.21% of the portfolio, ranked #92.

Pointe Capital Management first reported a position in REGN in Q4 2021 and has held it in 11 quarters since. The position peaked at $653K in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Pointe Capital Management held 757 shares of Regeneron Pharmaceuticals worth $472K as of Q2 2026.
Pointe Capital Management sold 60 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $40.8K.
Regeneron Pharmaceuticals made up 0.21% of Pointe Capital Management's portfolio in Q2 2026, its #92 holding.
Pointe Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Pointe Capital Management's Regeneron Pharmaceuticals position peaked at $653K in Q4 2025.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pointe Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.